JP2011500506A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011500506A5 JP2011500506A5 JP2009548186A JP2009548186A JP2011500506A5 JP 2011500506 A5 JP2011500506 A5 JP 2011500506A5 JP 2009548186 A JP2009548186 A JP 2009548186A JP 2009548186 A JP2009548186 A JP 2009548186A JP 2011500506 A5 JP2011500506 A5 JP 2011500506A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- nervous system
- day
- term
- oxygen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 11
- 210000003169 Central Nervous System Anatomy 0.000 claims 8
- 210000001428 Peripheral Nervous System Anatomy 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 8
- WTDRDQBEARUVNC-LURJTMIESA-N 3-hydroxy-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 6
- 101700024340 DDC Proteins 0.000 claims 6
- 102100016784 DDC Human genes 0.000 claims 6
- 101710007304 PAAS Proteins 0.000 claims 6
- 101710028148 TDC Proteins 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000003435 aroyl group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 201000009457 movement disease Diseases 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 125000004434 sulfur atoms Chemical group 0.000 claims 6
- 229940079593 drugs Drugs 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 206010014551 Emotional disease Diseases 0.000 claims 3
- 206010061536 Parkinson's disease Diseases 0.000 claims 3
- ILVXOBCQQYKLDS-UHFFFAOYSA-N Pyridine-N-oxide Chemical group [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 claims 3
- 125000002252 acyl group Chemical group 0.000 claims 3
- 125000001931 aliphatic group Chemical group 0.000 claims 3
- 125000004171 alkoxy aryl group Chemical group 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000003282 alkyl amino group Chemical group 0.000 claims 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 3
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 3
- 125000005325 aryloxy aryl group Chemical group 0.000 claims 3
- 125000004429 atoms Chemical group 0.000 claims 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 3
- 125000001589 carboacyl group Chemical group 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000004432 carbon atoms Chemical group C* 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000000460 chlorine Chemical group 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 125000002944 cyanoaryl group Chemical group 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 239000011737 fluorine Substances 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 125000006492 halo alkyl aryl group Chemical group 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 239000011630 iodine Chemical group 0.000 claims 3
- 229910052740 iodine Chemical group 0.000 claims 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 3
- 125000001624 naphthyl group Chemical group 0.000 claims 3
- 125000004999 nitroaryl group Chemical group 0.000 claims 3
- 150000002829 nitrogen Chemical class 0.000 claims 3
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N oxygen atom Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 125000004430 oxygen atoms Chemical group O* 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 230000004962 physiological condition Effects 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 230000000698 schizophrenic Effects 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 125000003107 substituted aryl group Chemical group 0.000 claims 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 3
- 239000011593 sulfur Substances 0.000 claims 3
- 125000004001 thioalkyl group Chemical group 0.000 claims 3
- 125000005000 thioaryl group Chemical group 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- YHKWFDPEASWKFQ-UHFFFAOYSA-N 3-nitrobenzene-1,2-diol Chemical compound OC1=CC=CC([N+]([O-])=O)=C1O YHKWFDPEASWKFQ-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Claims (29)
- 1日約2回から隔日に約1回の投与周期の投薬計画に従って投与する、中枢神経系及び末梢神経系に関連する疾患の予防または処置用薬剤の製造用の式I:
- 1日約2回から隔日に約1回の投与周期の投薬計画に従って投与する、中枢神経系及び末梢神経系に関連する疾患の予防または処置のための薬剤であって、式I:
- 前記投薬計画が1日1回である、請求項2に記載の薬剤。
- 前記投薬計画が1日2回である、請求項2に記載の薬剤。
- 前記投薬計画が隔日に1回である、請求項2に記載の薬剤。
- 前記中枢神経系及び末梢神経系に関連する疾患がL-DOPA及び/またはAADC治療によって治療可能である、請求項2〜5のいずれか1項に記載の薬剤。
- 前記中枢神経系及び末梢神経系に関連する疾患が、運動障害または統合失調性感情障害である、請求項2〜6のいずれか1項に記載の薬剤。
- 前記運動障害がパーキンソン病である、請求項7に記載の薬剤。
- 式Iの化合物が、5-[3-(2,5-ジクロロ-4,6-ジメチル-1-オキシ-ピリジン-3-イル)-[1,2,4]オキサジアゾール-5-イル]-3-ニトロベンゼン-1,2-ジオールである、請求項2〜8のいずれか1項に記載の薬剤。
- 投与間隔の開始点が、朝、昼、正午、午後、および真夜中を含む、請求項1〜9のいずれか1項に記載の薬剤。
- 投与間隔の開始点が夕方である、請求項1〜9のいずれか1項に記載の薬剤。
- さらにL-DOPAを含む、請求項2に記載の薬剤。
- さらにAADCを含む、請求項2に記載の薬剤。
- 式I:
- 前記投薬計画が1日1回である、請求項14に記載のパッケージ。
- 前記投薬計画が1日2回である、請求項14に記載のパッケージ。
- 前記投薬計画が隔日に1回である、請求項14に記載のパッケージ。
- 前記組成物が、L-DOPA及び/またはAADC治療によって治療可能な中枢神経系及び末梢神経系に関連する疾患の処置用である、請求項14〜17のいずれか1項に記載のパッケージ。
- 前記組成物が、運動障害または統合失調性感情障害である中枢神経系及び末梢神経系に関連する疾患の処置用である、請求項14〜18のいずれか1項に記載のパッケージ。
- 前記運動障害がパーキンソン病である、請求項19に記載のパッケージ。
- 式Iの化合物が5-[3-(2,5-ジクロロ-4,6-ジメチル-1-オキシ-ピリジン-3-イル)-[1,2,4]オキサジアゾール-5-イル]-3-ニトロベンゼン-1,2-ジオールである、請求項14〜20のいずれか1項に記載のパッケージ。
- 前記パッケージがさらにL-DOPA及び/またはAADCを含み、前記説明書がさらにL-DOPA及び/またはAADC投与に関連する説明書を含む、請求項14〜21のいずれか1項に記載のパッケージ。
- 前記投薬計画が1日1回である、請求項1に記載の使用。
- 前記投薬計画が1日2回である、請求項1に記載の使用。
- 前記投薬計画が隔日に1回である、請求項1に記載の使用。
- 前記中枢神経系及び末梢神経系に関連する疾患がL-DOPA及び/またはAADC治療によって治療可能である、請求項1に記載の使用。
- 前記中枢神経系及び末梢神経系に関連する疾患が、運動障害または統合失調性感情障害である、請求項1に記載の使用。
- 前記運動障害がパーキンソン病である、請求項27に記載の使用。
- 式Iの化合物が、5-[3-(2,5-ジクロロ-4,6-ジメチル-1-オキシ-ピリジン-3-イル)-[1,2,4]オキサジアゾール-5-イル]-3-ニトロベンゼン-1,2-ジオールである、請求項1に記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07002091.2 | 2007-01-31 | ||
EP07002091 | 2007-01-31 | ||
PCT/PT2007/000043 WO2008094053A1 (en) | 2007-01-31 | 2007-10-10 | Dosage regimen for comt inhibitors |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2011500506A JP2011500506A (ja) | 2011-01-06 |
JP2011500506A5 true JP2011500506A5 (ja) | 2011-06-02 |
JP5517629B2 JP5517629B2 (ja) | 2014-06-11 |
Family
ID=38961862
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009548186A Active JP5517629B2 (ja) | 2007-01-31 | 2007-10-10 | Comt阻害剤用の投薬計画 |
Country Status (24)
Country | Link |
---|---|
US (3) | US8524746B2 (ja) |
EP (2) | EP2124947B1 (ja) |
JP (1) | JP5517629B2 (ja) |
KR (1) | KR101522157B1 (ja) |
CN (1) | CN101631548B (ja) |
AR (2) | AR065098A1 (ja) |
AU (1) | AU2007346018A1 (ja) |
BR (1) | BRPI0721213B1 (ja) |
CA (1) | CA2678391C (ja) |
CY (1) | CY1118311T1 (ja) |
DK (2) | DK2124947T3 (ja) |
ES (2) | ES2644049T3 (ja) |
HR (1) | HRP20161261T8 (ja) |
HU (1) | HUE031317T2 (ja) |
IL (1) | IL200020A (ja) |
LT (1) | LT2481410T (ja) |
MX (1) | MX2009008051A (ja) |
NO (1) | NO20092905L (ja) |
PL (1) | PL2481410T3 (ja) |
PT (2) | PT2124947T (ja) |
RU (1) | RU2518483C2 (ja) |
SI (1) | SI2481410T1 (ja) |
WO (1) | WO2008094053A1 (ja) |
ZA (1) | ZA200905940B (ja) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL169855A (en) * | 2005-07-25 | 2014-05-28 | Elta Systems Ltd | A system and method for locating a receiver location |
BRPI0613859B8 (pt) | 2005-07-26 | 2021-05-25 | Bial Portela & Ca Sa | inibidores da comt, seus usos, e composição farmacêutica |
EP1845097A1 (en) | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
NZ577111A (en) | 2006-12-15 | 2012-05-25 | Abbott Lab | Novel oxadiazole compounds |
EP2124947B1 (en) | 2007-01-31 | 2017-07-19 | BIAL - Portela & Ca., S.A. | Dosage regimen for comt inhibitors |
MX2010009043A (es) * | 2008-02-28 | 2010-10-25 | Bial Portela & Ca Sa | Composicion farmaceutica para farmacos poco solubles. |
CA2718772C (en) * | 2008-03-17 | 2017-05-02 | David Alexander Learmonth | Crystal forms of 5-[3-(2,5-dichloro-4,6-dimethyl-1-oxy-pyridine-3-yl)[1,2,4]oxadiazol-5-yl]-3-nit robenzene-1,2-diol |
CN102355900A (zh) * | 2008-07-29 | 2012-02-15 | 比艾尔-坡特拉有限公司 | 硝基儿茶酚的给药方式 |
CN105878242A (zh) * | 2009-04-01 | 2016-08-24 | 巴尔-波特拉及康邦亚股份有限公司 | 包括硝基儿茶酚衍生物的药物制剂及其制备方法 |
CN102438595B (zh) * | 2009-04-01 | 2016-04-27 | 巴尔-波特拉及康邦亚股份有限公司 | 包括硝基儿茶酚衍生物的药物制剂及其制备方法 |
KR20120092175A (ko) | 2009-12-04 | 2012-08-20 | 죤 이. 그랜트 | 카테콜-0-메틸-트랜스퍼라제 저해제를 사용한 충동 제어 장애의 치료 |
US20140045900A1 (en) * | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
PT3604299T (pt) * | 2011-12-13 | 2023-10-31 | Bial Portela & Ca Sa | Composto químico útil como intermediário para a preparação de um inibidor de catecol-o-metiltransferase |
WO2016083863A1 (en) | 2014-11-28 | 2016-06-02 | Bial - Portela & Ca, S.A. | Medicaments for slowing parkinson's disease |
US9951057B2 (en) | 2015-01-30 | 2018-04-24 | Lieber Institute For Brain Development | COMT inhibiting methods and compositions |
EP3250209B1 (en) | 2015-01-30 | 2023-09-13 | Lieber Institute For Brain Development | Comt inhibiting methods and compositions |
EP3380471B8 (en) | 2015-11-25 | 2022-01-19 | Lieber Institute Inc. DBA Lieber Institute For Brain Development | Tetrahydro-8h-pyrido[1,2-a]pyrazine-8-ones as comt inhibitors for the treatment of neurodegenerative disorders |
WO2020072884A1 (en) | 2018-10-05 | 2020-04-09 | Neurocrine Biosciences, Inc. | Methods for the administration of comt inhibitors |
WO2020072886A1 (en) | 2018-10-05 | 2020-04-09 | Neurocrine Biosciences, Inc. | Methods for the administration of comt inhibitors |
USD912395S1 (en) * | 2019-11-01 | 2021-03-09 | Jondarius Brown | Apparatus for storing earphones |
GB202204798D0 (en) | 2022-04-01 | 2022-05-18 | Bial Portela & Ca Sa | Prodrugs of opicapone |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US660753A (en) * | 1899-11-27 | 1900-10-30 | Ferdinand-Christoph Von Heydebrand Und Der Lasa | Artificial fuel. |
US1532178A (en) | 1921-07-25 | 1925-04-07 | Louis A Godbold | Lubricator |
FR1260080A (fr) | 1960-03-22 | 1961-05-05 | Materiel De Forage Soc De Fab | Trépan à molettes étanche |
US3647809A (en) | 1968-04-26 | 1972-03-07 | Chinoin Gyogyszer Es Vegyeszet | Certain pyridyl-1 2 4-oxadiazole derivatives |
US4022901A (en) | 1975-03-05 | 1977-05-10 | E. R. Squibb & Sons, Inc. | 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles |
US4264573A (en) | 1979-05-21 | 1981-04-28 | Rowell Laboratories, Inc. | Pharmaceutical formulation for slow release via controlled surface erosion |
US4386668A (en) | 1980-09-19 | 1983-06-07 | Hughes Tool Company | Sealed lubricated and air cooled rock bit bearing |
DK175069B1 (da) | 1986-03-11 | 2004-05-24 | Hoffmann La Roche | Pyrocatecholderivater |
US5236952A (en) * | 1986-03-11 | 1993-08-17 | Hoffmann-La Roche Inc. | Catechol derivatives |
YU213587A (en) | 1986-11-28 | 1989-06-30 | Orion Yhtymae Oy | Process for obtaining new pharmacologic active cateholic derivatives |
DE3840954A1 (de) | 1988-12-05 | 1990-06-07 | Shell Int Research | Herstellung von 2-chlornicotinsaeureestern |
EP0462639A1 (en) | 1990-06-05 | 1991-12-27 | Shell Internationale Researchmaatschappij B.V. | Preparation of 2-chloropyridine derivatives |
EP0487774B1 (en) | 1990-11-29 | 1994-10-26 | Wei Ming Pharmaceutical Mfg. Co. Ltd. | A direct tabletting auxiliary |
EP0619814A1 (en) | 1991-12-31 | 1994-10-19 | Fujisawa Pharmaceutical Co., Ltd. | Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity |
GB9419274D0 (en) * | 1994-09-23 | 1994-11-09 | Orion Yhtymae Oy | New method for the preparation of 3,4-dihydroxy-5-nitrobenzaldehyde |
DE19628617A1 (de) | 1996-07-16 | 1998-01-22 | Basf Ag | Direkttablettierhilfsmittel |
US6206110B1 (en) | 1996-09-09 | 2001-03-27 | Smith International, Inc. | Protected lubricant reservoir with pressure control for sealed bearing earth boring drill bit |
JP2002526482A (ja) | 1998-09-18 | 2002-08-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | p38のインヒビター |
GB2344819A (en) | 1998-12-18 | 2000-06-21 | Portela & Ca Sa | 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones |
FI109453B (fi) | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
US6660753B2 (en) | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
BR0013427A (pt) | 1999-08-19 | 2002-07-30 | Nps Pharma Inc | Compostos heteropolicìclicos e seus usos como antagonistas no receptor de glutamato metabotrópico |
FI20000635A0 (fi) | 2000-03-17 | 2000-03-17 | Orion Yhtymae Oyj | COMT-inhibiittoreiden käyttö analgeettina |
SE0001438D0 (sv) | 2000-04-18 | 2000-04-18 | Axon Chemicals Bv | New chemical compounds and their use in therapy |
DE10029201A1 (de) | 2000-06-19 | 2001-12-20 | Basf Ag | Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung |
GB2363792A (en) * | 2000-06-21 | 2002-01-09 | Portela & Ca Sa | Nitrocatechols |
WO2002017175A1 (fr) | 2000-08-24 | 2002-02-28 | Sagawa Express Co., Ltd. | Procede de paiement par carte pour facturation de service concernant une distribution ou un transport physiques |
CN1166626C (zh) | 2000-08-30 | 2004-09-15 | 李凌松 | 三或四取代苯基化合物、其制备方法及应用 |
US20030027253A1 (en) | 2000-11-28 | 2003-02-06 | Presnell Scott R. | Cytokine receptor zcytor19 |
WO2002051442A1 (fr) | 2000-12-26 | 2002-07-04 | Takeda Chemical Industries, Ltd. | Co-prescriptions |
US20040097555A1 (en) | 2000-12-26 | 2004-05-20 | Shinegori Ohkawa | Concomitant drugs |
PL369598A1 (en) | 2001-02-21 | 2005-05-02 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
AU2002310187A1 (en) | 2001-05-30 | 2002-12-09 | Lg Biomedical Institute | Inhibitors of protein kinase for the treatment of disease |
KR20040004705A (ko) | 2001-06-08 | 2004-01-13 | 시토비아 인크. | 카스파제의 활성제 및 아폽토시스의 유도제로서의 치환된3-아릴-5-아릴-[1,2,4]-옥사디아졸과 유사체 및 이의 용도 |
ES2280602T3 (es) | 2001-07-26 | 2007-09-16 | Merck Patent Gmbh | Uso de 2-(5-(4-fluorofenil)-3-piridilmetilaminometil)-cromano y sus sales fisiologicamente aceptables. |
JP4379853B2 (ja) | 2001-10-05 | 2009-12-09 | 惠民製藥股▲分▼有限公司 | 直接錠剤化用調合物および補助剤の調合方法 |
WO2004058253A1 (en) | 2002-12-18 | 2004-07-15 | Cytovia, Inc. | 3,5-disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof |
WO2005006945A2 (en) | 2003-07-03 | 2005-01-27 | The Salk Institute For Biological Studies | Methods for treating neural disorders and compounds useful therefor |
US7226920B2 (en) | 2003-08-06 | 2007-06-05 | Vertex Pharmaceuticals Inc. | Aminotriazole compounds useful as inhibitors of protein kinases |
DE10338174A1 (de) | 2003-08-20 | 2005-03-24 | Lts Lohmann Therapie-Systeme Ag | Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit |
US7300406B2 (en) | 2003-09-30 | 2007-11-27 | Carter Vandette B | Medical examination apparatus |
GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
ATE464303T1 (de) | 2004-04-28 | 2010-04-15 | Vertex Pharma | Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen |
GB0510143D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
JP2008519811A (ja) | 2004-11-10 | 2008-06-12 | オリオン コーポレーション | 下肢静止不能症候群の治療 |
EP1827453A1 (en) | 2004-12-06 | 2007-09-05 | Themis Laboratories Private Limited | Sulfonylurea compositions and a process for its preparation |
US20080051441A1 (en) | 2004-12-28 | 2008-02-28 | Astrazeneca Ab | Aryl Sulphonamide Modulators |
JP2008525524A (ja) | 2004-12-28 | 2008-07-17 | アストラゼネカ・アクチエボラーグ | アリールスルホンアミドモジュレーター |
AU2006239418A1 (en) | 2005-04-26 | 2006-11-02 | Neurosearch A/S | Novel oxadiazole derivatives and their medical use |
US20060257473A1 (en) | 2005-05-11 | 2006-11-16 | Porranee Puranajoti | Extended release tablet |
GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
EP2298734A3 (en) | 2005-06-03 | 2011-07-13 | Abbott Laboratories | Cyclobutyl amine derivatives |
JP2007024970A (ja) | 2005-07-12 | 2007-02-01 | Miyakawa:Kk | 液晶表示装置の開口効率を上昇させるための樹脂レンズ製造法及びその製造装置 |
US20090000437A1 (en) | 2005-07-14 | 2009-01-01 | Provo Craft And Novelty, Inc. | Methods for Cutting |
BRPI0613859B8 (pt) | 2005-07-26 | 2021-05-25 | Bial Portela & Ca Sa | inibidores da comt, seus usos, e composição farmacêutica |
GB0515327D0 (en) * | 2005-07-26 | 2005-08-31 | Portela & Ca Sa | Comt inhibitors |
FR2889525A1 (fr) | 2005-08-04 | 2007-02-09 | Palumed Sa | Nouveaux derives de polyquinoleines et leur utilisation therapeutique. |
US20070048384A1 (en) | 2005-08-26 | 2007-03-01 | Joerg Rosenberg | Pharmaceutical compositions |
US20090111778A1 (en) | 2005-11-18 | 2009-04-30 | Richard Apodaca | 2-Keto-Oxazoles as Modulators of Fatty Acid Amide Hydrolase |
EP1956013B1 (en) | 2005-11-30 | 2016-04-13 | Fujifilm RI Pharma Co., Ltd. | Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition |
GB0606774D0 (en) | 2006-04-03 | 2006-05-10 | Novartis Ag | Organic compounds |
EP1845097A1 (en) | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
PE20080906A1 (es) | 2006-08-17 | 2008-07-05 | Kemia Inc | Derivados heteroarilo como inhibidores de citocina |
US20080167286A1 (en) | 2006-12-12 | 2008-07-10 | Abbott Laboratories | Pharmaceutical compositions and their methods of use |
US8486979B2 (en) | 2006-12-12 | 2013-07-16 | Abbvie Inc. | 1,2,4 oxadiazole compounds and methods of use thereof |
EP2124947B1 (en) | 2007-01-31 | 2017-07-19 | BIAL - Portela & Ca., S.A. | Dosage regimen for comt inhibitors |
WO2009029632A1 (en) | 2007-08-27 | 2009-03-05 | Helicon Therapeutics, Inc. | Therapeutic isoxazole compounds |
MX2010009043A (es) | 2008-02-28 | 2010-10-25 | Bial Portela & Ca Sa | Composicion farmaceutica para farmacos poco solubles. |
CA2718772C (en) | 2008-03-17 | 2017-05-02 | David Alexander Learmonth | Crystal forms of 5-[3-(2,5-dichloro-4,6-dimethyl-1-oxy-pyridine-3-yl)[1,2,4]oxadiazol-5-yl]-3-nit robenzene-1,2-diol |
CN102355900A (zh) | 2008-07-29 | 2012-02-15 | 比艾尔-坡特拉有限公司 | 硝基儿茶酚的给药方式 |
CN105878242A (zh) | 2009-04-01 | 2016-08-24 | 巴尔-波特拉及康邦亚股份有限公司 | 包括硝基儿茶酚衍生物的药物制剂及其制备方法 |
CN102438595B (zh) | 2009-04-01 | 2016-04-27 | 巴尔-波特拉及康邦亚股份有限公司 | 包括硝基儿茶酚衍生物的药物制剂及其制备方法 |
EA026419B1 (ru) | 2010-03-04 | 2017-04-28 | Орион Корпорейшн | Применение леводопы, карбидопы и энтакапона для лечения болезни паркинсона |
US20140045900A1 (en) | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
PT3604299T (pt) | 2011-12-13 | 2023-10-31 | Bial Portela & Ca Sa | Composto químico útil como intermediário para a preparação de um inibidor de catecol-o-metiltransferase |
-
2007
- 2007-10-10 EP EP07834911.5A patent/EP2124947B1/en active Active
- 2007-10-10 BR BRPI0721213-5A patent/BRPI0721213B1/pt active IP Right Grant
- 2007-10-10 ES ES07834911.5T patent/ES2644049T3/es active Active
- 2007-10-10 PT PT78349115T patent/PT2124947T/pt unknown
- 2007-10-10 DK DK07834911.5T patent/DK2124947T3/da active
- 2007-10-10 HU HUE12163797A patent/HUE031317T2/hu unknown
- 2007-10-10 JP JP2009548186A patent/JP5517629B2/ja active Active
- 2007-10-10 PT PT121637979T patent/PT2481410T/pt unknown
- 2007-10-10 SI SI200731839A patent/SI2481410T1/sl unknown
- 2007-10-10 KR KR1020097016752A patent/KR101522157B1/ko active IP Right Review Request
- 2007-10-10 PL PL12163797T patent/PL2481410T3/pl unknown
- 2007-10-10 AU AU2007346018A patent/AU2007346018A1/en not_active Abandoned
- 2007-10-10 RU RU2009132188/04A patent/RU2518483C2/ru active
- 2007-10-10 DK DK12163797.9T patent/DK2481410T3/en active
- 2007-10-10 WO PCT/PT2007/000043 patent/WO2008094053A1/en active Application Filing
- 2007-10-10 CA CA2678391A patent/CA2678391C/en active Active
- 2007-10-10 MX MX2009008051A patent/MX2009008051A/es active IP Right Grant
- 2007-10-10 CN CN200780050737.2A patent/CN101631548B/zh active Active
- 2007-10-10 US US12/524,848 patent/US8524746B2/en active Active
- 2007-10-10 LT LTEP12163797.9T patent/LT2481410T/lt unknown
- 2007-10-10 EP EP12163797.9A patent/EP2481410B1/en active Active
- 2007-10-10 ES ES12163797.9T patent/ES2597705T3/es active Active
-
2008
- 2008-01-30 AR ARP080100382A patent/AR065098A1/es not_active Application Discontinuation
-
2009
- 2009-07-22 IL IL200020A patent/IL200020A/en active IP Right Grant
- 2009-08-27 ZA ZA200905940A patent/ZA200905940B/xx unknown
- 2009-08-28 NO NO20092905A patent/NO20092905L/no not_active Application Discontinuation
-
2013
- 2013-07-25 US US13/950,661 patent/US20130331416A1/en not_active Abandoned
-
2015
- 2015-04-17 US US14/689,397 patent/US9745290B2/en active Active
-
2016
- 2016-10-03 HR HRP20161261TT patent/HRP20161261T8/hr unknown
- 2016-10-12 CY CY20161101012T patent/CY1118311T1/el unknown
-
2017
- 2017-09-08 AR ARP170102484A patent/AR109590A2/es not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2011500506A5 (ja) | ||
RU2009132188A (ru) | Режим дозирования ингибиторов комт | |
RU2013139414A (ru) | Режим введения для нитрокатехолов | |
JP2012092149A5 (ja) | ||
US20090264443A1 (en) | Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds | |
JP2016185995A5 (ja) | ||
HRP20120323T4 (hr) | Spoj diaril-hidantoina | |
RU2010154173A (ru) | Режим введения нитрокатехолов | |
CY1111159T1 (el) | Πυκνα διαλυματα μεθοτρεξατης | |
JP2014505096A5 (ja) | ||
RU2010107284A (ru) | Производные нафтиридина в качестве модуляторов калиевых каналов | |
UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
NO20070979L (no) | Anvendelse av N-aryldiazaspirasykliske forbindelser i behandling av avhengighet | |
ATE302774T1 (de) | Arzneimittel enthaltend betamimetika und ein neues anticholinergikum | |
RU2008112181A (ru) | Применение конденсированных производных имидазола для лечения заболеваний, опосредованных рецептором ccr3 | |
RU2006131308A (ru) | Гетероциклически замещенные производные 7-амино-4-хинолон-3-карбоновых кислот, способ их получения и их применение в качестве лекарственных средств | |
JP2016525104A5 (ja) | ||
JP2019520344A5 (ja) | ||
EP2670405B1 (en) | Combinations comprising macitentan for the treatment of glioblastoma multiforme | |
JP2014512355A5 (ja) | ||
JP2011500805A5 (ja) | ||
CL2008001332A1 (es) | Uso de temozolomida para preparar un medicamento util para el tratamiento de un desorden proliferativo. | |
RU2012108144A (ru) | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами | |
RU2016111390A (ru) | Неконкурентные антагонисты никотиновых рецепторов | |
RU2016110546A (ru) | Комбинированная лекарственная терапия |